Zoetis Stock Faces Price Target Cuts After Tough Q1 Update

Zoetis (ZTS) is back in focus as analysts recalibrate their price targets, with Citi cutting its view to $112 from $145 while other firms move to $95 and $115 after a sharp reset in sentiment. These changes track closely with a Q1 update that some call "difficult" and "worse than it seems," even as bullish voices highlight the company's premium portfolio and revised 2026 guidance. The following sections explain how to interpret these shifting targets and keep up with the evolving analyst views.

Recommendation Change

Citi lowered its price target for Zoetis from $145 to $112, a decline of about 23%. Other analysts set targets at $95 and $115, reflecting a divergence in views on the stock's valuation after the update.

Analyst Rationale

Analysts believe the Q1 update was "difficult," with pressure on sales and margins. Some consider the update "worse than it seems," prompting a reassessment of future growth. However, optimists still focus on Zoetis's premium veterinary portfolio and revised 2026 guidance, which may support the stock long-term.

Context

These changes come as the animal health sector faces input cost pressures and shifting demand. Zoetis's stock has been under pressure recently, down X% year-to-date (based on available data). Compared to peers like Elanco and IDEXX, Zoetis maintains a strong competitive position but valuations vary.

What to Make of It

The recent price target adjustments reflect uncertainty about Zoetis's near-term prospects. Investors are advised to monitor upcoming quarterly reports and assess whether the revised guidance materializes. It is recommended to rely on multiple analyses and not on a single analyst recommendation.